Application of lercanidipine in the treatment of hypertension

Abstract

The article presents data from clinical trials that have examined the efficacy and safety of modern calcium antagonist (CA) III generation of lercanidipine. The results of studies show that treatment with lercanidipine leads to a marked reduction in systolic and diastolic blood pressure without significant effect on heart rate. Unique pharmacokinetic characteristics of the drug provide its excellent efficacy and safety, good tolerability, convenience, acceptance and high adherence CA data in patients with hypertension. Additional properties of lercanidipine allow us to recommend the use of the CA in comorbidity.

Keywords

• lercanidipine lerkamen
• dihydropyridines calcium antagonists generation iii
• randomized clinical trials
• hypertension